PRDS | Jotup

Pardes Biosciences Announces Closing of Tender Offer

Retrieved on:

Thursday, August 31, 2023

Intellectual property, SVB Securities, CVR, Sub, COVID-19, Foresite Capital, Expiration date, Mergers and acquisitions, PRDS, Expiration, Cryptocurrency, Pardes

The tender offer and related withdrawal rights expired at one minute after 11:59 p.m. Eastern Time on August 30, 2023 (the Expiration Date).

Key Points:

The tender offer and related withdrawal rights expired at one minute after 11:59 p.m. Eastern Time on August 30, 2023 (the Expiration Date).
As of the Expiration Date, a total of 37,836,066 shares of Pardes common stock were validly tendered, and not validly withdrawn, representing approximately 60.9% of the outstanding shares of Pardes common stock as of the Expiration Date.
As of the Expiration Date, the number of shares validly tendered in accordance with the terms of the tender offer and not validly withdrawn satisfied the minimum tender condition, and all other conditions to the offer were satisfied or waived.
Following the closing of the tender offer, Merger Sub merged with and into Pardes and all shares of Pardes common stock that had not been validly tendered were converted into the right to receive the Offer Price (the Merger).

MediPacific Offering $2.13 Per Share Plus One Contingent Value Right Per Share in Tender Offer for Pardes Biosciences

Retrieved on:

Monday, August 28, 2023

Pursuant to the Merger Agreement, on July 28, 2023, Purchaser and Parent commenced a tender offer for any or all of Pardes’ outstanding shares of common stock (the “Offer”).

Key Points:

Pursuant to the Merger Agreement, on July 28, 2023, Purchaser and Parent commenced a tender offer for any or all of Pardes’ outstanding shares of common stock (the “Offer”).
As a result, Pardes stockholders that tender their shares in the Offer will receive (i) $2.13 per share and (ii) one non-transferable CVR per share in accordance with the terms of the Offer.
Pardes’ stockholders and other investors can obtain the Tender Offer Statement, the Solicitation/Recommendation Statement, the Schedule 13E-3 and other filed documents for free at the SEC’s website at www.sec.gov .
In addition, Pardes’ stockholders may obtain free copies of the Offer materials by contacting Innisfree M&A Incorporated, the information agent for the Offer.

ALERT: The M&A Class Action Firm Continues Investigating the Merger – AMNB, RETA, CIR, PRDS

Retrieved on:

Monday, August 21, 2023

CVR, Reata Pharmaceuticals, CIR, KKR, Empire, Sale, PRDS, Control, Biogen, Monteverde, NYSE, Security (finance)

Under the terms of the agreement, AMNB shareholders will receive 1.35 shares of Atlantic per share they own.

Key Points:

Under the terms of the agreement, AMNB shareholders will receive 1.35 shares of Atlantic per share they own.
It is free and there is no cost or obligation to you.
Under the terms of the agreement, RETA shareholders are expected to receive $172.50 in cash per share they own.
Under the terms of the agreement, CIR shareholders will receive $49.00 in cash per share they own.

ALERT: The M&A Class Action Firm Continues Investigating the Merger – PRDS, CIR, RETA, AMNB

Retrieved on:

Monday, August 14, 2023

CVR, CIR, Reata Pharmaceuticals, KKR, Empire, Sale, PRDS, Control, Biogen, Monteverde, NYSE, Security (finance)

It is free and there is no cost or obligation to you.

Key Points:

It is free and there is no cost or obligation to you.
CIRCOR International, Inc. (NYSE: CIR ), relating to its proposed sale to funds managed by KKR.
American National Bankshares Inc. (Nasdaq: AMNB ), relating to its proposed sale to Atlantic Union Bankshares Corp.
Under the terms of the agreement, AMNB shareholders will receive 1.35 shares of Atlantic per share they own.

MediPacific Announces Calculation of Additional Price Per Share and Extension of Expiration Date for Tender Offer for Pardes Biosciences Shares

Retrieved on:

Thursday, August 17, 2023

Pursuant to the Merger Agreement, on July 28, 2023, Purchaser and Parent commenced a tender offer for any or all of Pardes’ outstanding shares of common stock (the “Offer”).

Key Points:

Pursuant to the Merger Agreement, on July 28, 2023, Purchaser and Parent commenced a tender offer for any or all of Pardes’ outstanding shares of common stock (the “Offer”).
Pursuant to the terms of the Merger Agreement, Parent, Purchaser and Pardes have determined that the Additional Price Per Share, based on Pardes’ expected net cash, is $0.11 per share.
Accordingly, the total cash amount that Purchaser will pay pursuant to the terms of the Offer and the Merger Agreement is $2.13 per share.
Stockholders that have previously tendered their shares do not need to re-tender their shares or take any other action in response to the determination of the Additional Price Per Share or extension of the Offer expiration date.

SHAREHOLDER ALERT: The M&A Class Action Firm Continues Investigating the Merger – CIR, PRDS, NEWR, QUOT

Retrieved on:

Monday, August 7, 2023

Quotient, CVR, New Relic, CIR, KKR, Empire, Sale, PRDS, Control, Francisco Partners, Monteverde, NYSE, Security (finance)

Under the terms of the agreement, CIR shareholders will receive $49.00 in cash per share they own.

Key Points:

Under the terms of the agreement, CIR shareholders will receive $49.00 in cash per share they own.
It is free and there is no cost or obligation to you.
Under the terms of the agreement, NEWR shareholders will receive $87.00 in cash per share they own.
Under the terms of the agreement, QUOT shareholders are expected to receive $4.00 in cash per share they own.

ALERT: The M&A Class Action Firm Continues Investigating the Merger – NEWR, QUOT, CIR, PRDS

Retrieved on:

Monday, July 31, 2023

Quotient, CVR, New Relic, CIR, KKR, Empire, Sale, PRDS, Control, Francisco Partners, Monteverde, NYSE, Security (finance)

Under the terms of the agreement, NEWR shareholders will receive $87.00 in cash per share they own.

Key Points:

Under the terms of the agreement, NEWR shareholders will receive $87.00 in cash per share they own.
It is free and there is no cost or obligation to you.
Quotient Technology Inc. (NYSE: QUOT ), relating to its proposed sale to Neptune Retail Solutions.
Under the terms of the agreement, QUOT shareholders are expected to receive $4.00 in cash per share they own.

ALERT: The M&A Class Action Firm Continues Investigating the Merger – CIR, AAIC, QUOT, PRDS

Retrieved on:

Tuesday, July 25, 2023

Quotient, CVR, CIR, KKR, Empire, Sale, PRDS, AAIC, Control, Monteverde, NYSE, Security (finance)

NEW YORK, July 24, 2023 (GLOBE NEWSWIRE) -- Juan Monteverde, founder and managing partner of the class action firm Monteverde & Associates PC (the “M&A Class Action Firm”), a national securities firm rated Top 50 in the 2018-2021 ISS Securities Class Action Services Report and headquartered at the Empire State Building in New York City, is investigating:

Key Points:

Under the terms of the agreement, CIR shareholders will receive $49.00 in cash per share they own.
Arlington Asset Investment Corp. (NYSE: AAIC ), relating to its proposed sale to Ellington Financial Inc.
Under the terms of the agreement, AAIC shareholders will receive 0.3619 shares of Ellington and $0.09 in cash per share they own.
Under the terms of the agreement, QUOT shareholders are expected to receive $4.00 in cash per share they own.

Lifshitz Law PLLC Announces Investigations of HCCI, PRDS, NLTX, CCF

Retrieved on:

Sunday, July 23, 2023

Telephone, CCF, PRDS, HCCI, Advertising, KKR, Hewlett, Sale, Financial adviser, Online shopping

Lifshitz Law PLLC announces an investigation into possible breach of fiduciary duties in connection with the sale of HCCI to an investment affiliate of J.F.

Key Points:

Lifshitz Law PLLC announces an investigation into possible breach of fiduciary duties in connection with the sale of HCCI to an investment affiliate of J.F.
Lifshitz Law PLLC announces an investigation into possible breach of fiduciary duties in connection with the merger of NLTX and Neurogene Inc.
Lifshitz Law PLLC announces an investigation into possible breach of fiduciary duties in connection with the sale of CCF to an affiliate of investment funds managed by KKR for $127.50 per share in cash for each share of CCF common stock owned.
The law firm responsible for this advertisement is Lifshitz Law PLLC, 1190 Broadway, Hewlett, New York 11557, Tel: (516)493-9780.

INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Pardes Biosciences, Inc. and Encourages Investors with Losses to Contact the Firm

Retrieved on:

Wednesday, July 19, 2023

Professional Services, Class Action Lawsuit, Ethics, Suite, PRDS, Pardes, Security (finance)

The investigation focuses on determining if the Pardes board breached its fiduciary duties to shareholders by failing to conduct a fair process prior to the agreement, and whether MediPacific is underpaying for the Company.

Key Points:

The investigation focuses on determining if the Pardes board breached its fiduciary duties to shareholders by failing to conduct a fair process prior to the agreement, and whether MediPacific is underpaying for the Company.
We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge.
The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.